Program
2019-nCoV Vaccine mRNA-1273
Also written as “mRNA-1273”, “mRNA-1273.815” and “mRNA-1273.529”.
Its studies are mostly in COVID-19 · Coronavirus Infections · Papillomavirus Infections · Influenza, Human, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Moderna | 173 open or running | phase 4since Sep 3, 2024 | May 13, 2020 | Dec 11, 2026phase 4 · NCT07863635 |
| Merck | 10 open or running | phase 3since Nov 10, 2021 | Nov 10, 2021 | none ahead |
| Regeneron Pharmaceuticals | 10 open or running | phase 2since Apr 19, 2021 | Apr 19, 2021 | none ahead |
| Takeda | 10 open or running | phase 2since Dec 18, 2020 | Dec 18, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since May 13, 2020.
- Apr 19, 2021Regeneron Pharmaceuticals’ first study: phase 2 study in HealthyNew to Regeneron PharmaceuticalsRegeneron Pharmaceuticals · NCT04852978 · 295 enrolled · United States
- Apr 21, 2021Phase 3 study in Coronavirus InfectionsModerna · NCT04860297 · 234 enrolled · United States
- Jun 14, 2021Phase 3 study in Coronavirus InfectionsModerna · NCT04927065 · 5,161 enrolled · United States
- Nov 10, 2021Merck’s first study: phase 3 study in Papillomavirus InfectionsNew to MerckMerck · NCT05119855 · 165 enrolled · United States
- Feb 19, 2022Phase 3 study in Coronavirus InfectionsModerna · NCT05249829 · 3,548 enrolled · United Kingdom
- May 13, 2022Phase 2 study in Influenza, HumanModerna · NCT05375838 · 550 enrolled · United States
- May 25, 2022Phase 1 study in Coronavirus InfectionsModerna · NCT05397223 · 308 enrolled · United States
- Jun 27, 2022Phase 3 study in COVID-19Moderna · NCT05436834 · 1,807 enrolled · United States, Argentina, Chile and more
- Apr 13, 2023Phase 3 study in COVID-19Moderna · NCT05815498 · 13,553 enrolled · United States, Canada, Japan and more
- Apr 5, 2024Phase 3 study in Coronavirus InfectionsModerna · NCT06354998 · 217 enrolled · Australia
- Sep 3, 2024Phase 4 study in Coronavirus InfectionsModerna · NCT06585241 · 1,144 planned · United States
- Oct 8, 2024Phase 4 study in Healthy VolunteersModerna · NCT06634797 · 1,000 enrolled · United States
- Nov 25, 2025Phase 4 study in Coronavirus InfectionsModerna · NCT07266558 · 30,000 enrolled · United States
- Oct 2, 2026Phase 4 study in Coronavirus InfectionsModerna · NCT07863635 · 600 planned · United States
Ahead
- Dec 11, 2026Primary completion: phase 4 study in Coronavirus InfectionsModerna · NCT07863635
- Dec 31, 2026Primary completion: phase 4 study in Coronavirus InfectionsModerna · NCT06585241
- Jun 16, 2027Primary completion: phase 4 study in Coronavirus InfectionsModerna · NCT07266558
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“A vaccine consisting of a lipid nanoparticle (LNP) encapsulating a messenger RNA (mRNA) encoding the full-length, prefusion stabilized spike (S) protein of SARS-CoV-2, ”NCIt, by rule
“Spike glycoprotein vaccine antigen”ChEMBL 37, by rule
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07863635Coronavirus Infections · United States | 4 | Recruiting | Moderna | Dec 11, 2026 | 600 |
| NCT07266558Coronavirus Infections · United States | 4 | Active, not recruiting | Moderna | Jun 16, 2027 | 30,000 |
| NCT06634797Healthy Volunteers · United States | 4 | Completed | Moderna | Jan 20, 2025 | 1,000 |
| NCT06585241Coronavirus Infections · United States | 4 | Recruiting | Moderna | Dec 31, 2026 | 1,144 |
| NCT06354998Coronavirus Infections · Australia | 3 | Completed | Moderna | May 10, 2024 | 217 |
| NCT05815498COVID-19 · United States, Canada, Japan and more | 3 | Completed | Moderna | Apr 12, 2025 | 13,553 |
| NCT05436834COVID-19 · United States, Argentina, Chile and more | 3 | Completed | Moderna | Oct 20, 2025 | 1,807 |
| NCT05397223Coronavirus Infections · United States | 1 | Completed | Moderna | Feb 27, 2026 | 308 |
| NCT05375838Influenza, Human · United States | 2 | Completed | Moderna | Dec 29, 2022 | 550 |
| NCT05249829Coronavirus Infections · United Kingdom | 3 | Completed | Moderna | Jun 23, 2023 | 3,548 |
| NCT05119855Papillomavirus Infections · United States | 3 | Completed | Merck | Dec 12, 2023 | 165 |
| NCT04927065Coronavirus Infections · United States | 3 | Completed | Moderna | Nov 17, 2023 | 5,161 |
| NCT04860297Coronavirus Infections · United States | 3 | Completed | Moderna | May 22, 2023 | 234 |
| NCT04852978Healthy · United States | 2 | Completed | Regeneron Pharmaceuticals | Nov 21, 2022 | 295 |
| NCT04813796Coronavirus Infections · United States | 1 | Completed | Moderna | Jul 25, 2023 | 104 |
| NCT04796896Coronavirus Infections · United States, Canada | 3 | Completed | Moderna | Mar 15, 2024 | 11,942 |
| NCT04677660COVID-19 · Japan | 2 | Completed | Takeda | Feb 22, 2022 | 200 |
| NCT04649151Coronavirus Infections · United States, Dominican Republic | 3 | Completed | Moderna | Jun 14, 2024 | 4,328 |
| NCT04470427Coronavirus Infections · United States | 3 | Completed | Moderna | Dec 29, 2022 | 30,415 |
| NCT04405076Coronavirus Infections · United States | 2 | Completed | Moderna | Oct 28, 2021 | 660 |
How it is read
Names in the registry
- “mRNA-1273”, 10 entries
- “mRNA-1273.815”, 3 entries
- “mRNA-1273.529”, 2 entries
- “mRNA-1273 Variant-containing Formulation”, 1 entry
- “mRNA-1273 Vaccine”, 1 entry
Codes read as this program: MRNA1273.
Conditions, from the studies’ own filings
- COVID-19, 15 studies
- Coronavirus Infections, 1 study
- Papillomavirus Infections, 1 study
- Influenza, Human, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.